ORGANOIDSCIENCES
Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-… Read more
ORGANOIDSCIENCES (476040) - Total Liabilities
Latest total liabilities as of December 2024: ₩10.58 Billion KRW
Based on the latest financial reports, ORGANOIDSCIENCES (476040) has total liabilities worth ₩10.58 Billion KRW as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ORGANOIDSCIENCES - Total Liabilities Trend (2021–2024)
This chart illustrates how ORGANOIDSCIENCES's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ORGANOIDSCIENCES Competitors by Total Liabilities
The table below lists competitors of ORGANOIDSCIENCES ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Keramika Indonesia Assosiasi
JK:KIAS
|
Indonesia | Rp180.50 Billion |
|
SHIONOGI & CO LTD - Dusseldorf Stock Exchang
DU:SH0
|
Germany | €164.36 Billion |
|
FUJI HEAVY IND
BE:FUH
|
Germany | €2.46 Trillion |
Liability Composition Analysis (2021–2024)
This chart breaks down ORGANOIDSCIENCES's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.35 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ORGANOIDSCIENCES's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ORGANOIDSCIENCES (2021–2024)
The table below shows the annual total liabilities of ORGANOIDSCIENCES from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩10.58 Billion | -90.39% |
| 2023-12-31 | ₩110.09 Billion | +38.80% |
| 2022-12-31 | ₩79.32 Billion | +48.97% |
| 2021-12-31 | ₩53.24 Billion | -- |